Kodiak Sciences

Kodiak Sciences

Kodiak Sciences was founded in 2009 by Victor Perlroth, an entrepreneur and physician by training, who aimed to build a biotech platform around an antibody biopolymer conjugate technology for retinal disease. The company is structured not as a family office but as a publicly traded clinical-stage biopharmaceutical firm, with a single asset concentration that defines its risk profile. Kodiak's strategy revolves entirely around its lead investigational therapy, tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer conjugate designed to extend treatment intervals for patients with wet age-related macular degeneration and diabetic macular edema. The firm's work cuts across clinical development, regulatory strategy, and novel drug formulation, with a geographic footprint that spans trial sites in North America, Europe, and Asia. Despite having raised hundreds of millions in public equity — notably a $225 million financing in 2020 — the company's fate is tied to the binary outcomes of pivotal Phase 3 trials. Kodiak has approximately 32 full-time employees and operates from a single headquarters in Palo Alto, California. In July 2023, the company announced that tarcocimab tedromer failed to meet its primary endpoint in two pivotal Phase 3 studies, a disclosure that sent the stock down over 80% and forced a strategic restructuring. The firm does not maintain a venture arm or philanthropic foundation, and there are no disclosed adjacent vehicles. The structural differentiator for Kodiak is its deep operational tie to a single binary asset — a posture more akin to a project-financed pharmaceutical engine than a diversified biotech platform. The company's remaining value rests on a separate Phase 3 study for a different delivery formulation and indication, while its balance sheet holds enough cash to fund operations through 2025 without additional capital. This concentration risk, unusual even among single-product biotechs, defines every decision the company makes.